Dr Agarwal's Hea
Dr Agarwal's Hea Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
Q1 FY27 revenue from operations grew 26% year-on-year to INR614 crores, driven by both volume and value growth (~16% each). Q1 FY27 showed strong revenue growth of 26% YoY and Ind AS EBITDA growth of 25.2% with margin improvement.
From Dr Agarwal's Hea's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Q1 FY27 revenue from operations grew 26% year-on-year to INR614 crores, driven by both volume and value growth (~16% each).
- Same-store sales growth (SSSG) for mature facilities (pre-FY23) was strong at 16.3%, with new centers showing even higher growth.
- Patient volume growth expected to continue, supported by technology upgrades and insurance expansion.
- Premiumization and price hikes contributed ~8% to value growth.
- Expansion of network with 60 new facilities planned for FY27 (40 surgical centers), maintaining aggressive greenfield growth.
- Increasing adoption of advanced, higher-margin surgical procedures like Femto cataract and robotic surgeries expected to boost average realization per surgery.
- Focus on deeper market penetration, especially in mature South region; North and West regions showing significant growth opportunities.
- Merge completion expected by mid-November 2026, supporting operational synergies and growth momentum.
- Overall outlook remains positive with sustained volume and revenue growth anticipated.
Profitability & Margins
See what Dr Agarwal's Hea said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Dr. Agarwal's Healthcare continues a strong expansion strategy with a large capital investment in greenfield facilities.
- In Q1 FY27 alone, 18 new greenfield facilities were commissioned, including 1 large tertiary and 15 secondary facilities across various states.
- The company plans to add 60 new facilities in FY27, including 40 surgical centers, with 12 facilities targeted for Q2 and 30 in the latter half of the year.
- There is a strong pipeline with 30+ signed Letters of Intent (LOIs) for upcoming greenfield projects.
- Expansion focuses on geographic diversification and deepening market penetration, including significant growth in Delhi NCR region with 8 facilities currently and 3 to 5 more planned within the year.
- Ongoing investment in advanced surgical technology and innovative procedures continues to drive strategic clinical excellence.
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Dr Agarwal's Hea said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention the current or expected order book or pending orders.
- However, it states a strong pipeline of greenfield projects with "30-plus signed Letters of Intent (LOIs)" already in place.
- The company plans to add 60 new facilities in FY27, including 40 surgical centers.
- Expansion plans include adding 12 facilities in Q2 and 30 in the second half of the year.
- The greenfield execution engine is described as "firing" with strong pipeline and signed agreements, indicating robust upcoming projects and orders.
- No specific order book value or financial quantification of pending orders is provided.
Dr Agarwal's Hea — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹564 Cr, net profit ₹50 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Dr Agarwals Health Care Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Manipal Health Enterprises Ltd (Q1 FY27)
Volume-led growth with inpatient (IP) volumes up 39% and outpatient (OP) volumes up 26% year-on-year. Key concall takeaways from Manipal Health Enterprises…
- Fortis Healthcare Ltd (Q1 FY27)
IHH plans to increase its stake in Fortis to over 50% within 3-5 years, supporting long-term strategic growth. Key concall takeaways from Fortis Healthcare…
- Metropolis Healthcare Ltd (Q1 FY27)
East India currently 6%, with limited investment so far; future investments may increase contribution. Key concall takeaways from Metropolis Healthcare Ltd's…
- Apollo Hospitals Enterprise Ltd (Q1 FY27)
IP volume growth for established units guided at roughly 7% to 8%. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings call — and how…
Frequently Asked Questions
What were Dr Agarwal's Hea Q1 FY27 results?
Q1 FY27 revenue from operations grew 26% year-on-year to INR614 crores, driven by both volume and value growth (~16% each). Q1 FY27 showed strong revenue growth of 26% YoY and Ind AS EBITDA growth of 25.2% with margin improvement.
What is Dr Agarwal's Hea share price analysis?
Dr Agarwal's Hea currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 107.4 with a market cap of ₹15,858 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dr Agarwal's Hea planning capital expenditure?
Dr.
Keep Dr Agarwal's Hea on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.